{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T23:40:25Z","timestamp":1720741225488},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.vhri.2018.05.002","type":"journal-article","created":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T23:55:07Z","timestamp":1537055707000},"page":"99-105","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector"],"prefix":"10.1016","volume":"16","author":[{"given":"Nericke","family":"Olivier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martie","family":"Lubbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rianda","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Naud\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanita","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2018.05.002_bib0001","unstructured":"The Arthritis Foundation of South Africa. Conditions and treatments. Available from: http:\/\/www.arthritis.org.za\/Treatments\/. [Accessed June 28, 2016]."},{"key":"10.1016\/j.vhri.2018.05.002_bib0002","series-title":"Presented at: ISPOR South Africa Chapter Annual Conference and Short Courses","article-title":"The value of registries: the SARAA registry 2017","author":"Van Duuren","year":"2017"},{"key":"10.1016\/j.vhri.2018.05.002_bib0003","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/JOM.0b013e318282d310","article-title":"Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis","volume":"55","author":"Kleinman","year":"2013","journal-title":"J Occup Environ Med"},{"key":"10.1016\/j.vhri.2018.05.002_bib0004","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/acr.21755","article-title":"Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey","volume":"64","author":"Kawatkar","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.vhri.2018.05.002_bib0005","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s10067-016-3277-y","article-title":"Comorbid conditions are associated with healthcare utilization, medical charges and mortality of patients with rheumatoid arthritis","volume":"35","author":"Han","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vhri.2018.05.002_bib0007","first-page":"869","article-title":"The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis: results from 34 countries participating in the Quest-RA program","volume":"32","author":"Gr\u00f8n","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.vhri.2018.05.002_bib0008","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1521-6942(03)00041-X","article-title":"Co-morbidity in rheumatoid arthritis","volume":"17","author":"Mikuls","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.vhri.2018.05.002_bib0009","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jbspin.2013.01.013","article-title":"Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis","volume":"80","author":"Osiri","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.vhri.2018.05.002_bib0010","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s10198-007-0088-8","article-title":"The burden of rheumatoid arthritis and access to treatment: health burden and costs","volume":"8","author":"Lundkvist","year":"2008","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vhri.2018.05.002_bib0011","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jbspin.2004.01.003","article-title":"Rheumatoid arthritis: direct and indirect costs","volume":"71","author":"Rat","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.vhri.2018.05.002_bib0012","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10067-010-1634-9","article-title":"The burden of illness of rheumatoid arthritis","volume":"30","author":"Boonen","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vhri.2018.05.002_bib0013","unstructured":"US Forex. Historical exchange rates. Available from: https:\/\/www.ofx.com\/en-au\/forex-news\/historical-exchange-rates\/yearly-average-rates\/. [Accessed March 20, 2018]."},{"key":"10.1016\/j.vhri.2018.05.002_bib0014","unstructured":"South African Department of Health. National health insurance for South Africa: towards universal health coverage. Available from: http:\/\/www.health.gov.za\/index.php\/component\/phocadownload\/category\/383#. [Accessed September 11, 2017]."},{"key":"10.1016\/j.vhri.2018.05.002_bib0016","unstructured":"South African Council for Medical Schemes. Chronic disease list. Which chronic diseases are covered? Available from: https:\/\/www.medicalschemes.com\/medical_schemes_pmb\/chronic_disease_list.htm. [Accessed August 10, 2017]."},{"key":"10.1016\/j.vhri.2018.05.002_bib0018","unstructured":"South African Council for Medical Schemes. Rheumatoid arthritis. Available from: https:\/\/www.medicalschemes.com\/files\/Prescribed%20Minimum%20Benefits\/RheumathoidArthritis.pdf. [Accessed March 14, 2018]."},{"key":"10.1016\/j.vhri.2018.05.002_bib0019","unstructured":"US Food and Drug Administration. Enbrel\u00ae (etanercept) prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf. [Accessed April 12, 2018]."},{"key":"10.1016\/j.vhri.2018.05.002_bib0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7196\/SAMJ.7047","article-title":"South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013","volume":"103","author":"Hodkinson","year":"2013","journal-title":"S Afr Med J"},{"key":"10.1016\/j.vhri.2018.05.002_bib0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/clpt.2011.278","article-title":"Biologics-based therapy for the treatment of rheumatoid arthritis","volume":"91","author":"Scott","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vhri.2018.05.002_bib0022","first-page":"37","article-title":"The impact of rheumatoid arthritis and biologics on employers and payers","volume":"5","author":"Chaudhari","year":"2008","journal-title":"Biotechnol Healthc"},{"key":"10.1016\/j.vhri.2018.05.002_bib0023","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/annrheumdis-2013-204311","article-title":"Evolution of cost structures in rheumatoid arthritis over the past decade","volume":"74","author":"Husher","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vhri.2018.05.002_bib0025","series-title":"Prescribing Patterns of Biologic Immunomodulating Medicine in the South African Private Health Care Sector. Potchefstroom","author":"Roux","year":"2010"},{"key":"10.1016\/j.vhri.2018.05.002_bib0026","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"The use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.vhri.2018.05.002_bib0027","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7196\/SAMJ.8947","article-title":"Superheroes in autoimmune warfare: biologic therapies in current South African practice","volume":"104","author":"Tarr","year":"2014","journal-title":"S Afr Med J"},{"key":"10.1016\/j.vhri.2018.05.002_bib0028","unstructured":"Council for Medical Schemes. Managed care organisations. Available from: https:\/\/www.medicalschemes.com\/ManagedCareOrganisations.aspx. [Accessed June 30, 2017]."},{"key":"10.1016\/j.vhri.2018.05.002_bib0030","unstructured":"SAS Institute. Statistical Analysis System\u00ae (SAS 9.4\u00ae). Cary, NC: SAS Institute, 2002\u20132012."},{"key":"10.1016\/j.vhri.2018.05.002_bib0031","series-title":"First Steps in Research","article-title":"Overview of some of the most popular statistical techniques","author":"Petersen","year":"2016"},{"key":"10.1016\/j.vhri.2018.05.002_bib0032","unstructured":"Swanepoel JWH, Swanepoel CJ, Van Graan FC, et\u00a0al. Elementary Statistical Methods (3rd ed.). Potchefstroom, South Africa: AndCork, 2010."},{"key":"10.1016\/j.vhri.2018.05.002_bib0033","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4137\/CMAMD.S11481","article-title":"Comorbidity profiles among patients with rheumatoid arthritis and the impact on prescription trends","volume":"6","author":"Al-Bishri","year":"2013","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"issue":"49","key":"10.1016\/j.vhri.2018.05.002_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2014.01.027","article-title":"Diagnosis and classification of rheumatoid arthritis","volume":"48","author":"Kourilovitch","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vhri.2018.05.002_bib0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","article-title":"Epidemiology of adult rheumatoid arthritis","volume":"4","author":"Alamanos","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.vhri.2018.05.002_bib0036","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00296-013-2782-4","article-title":"Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from national claims database","volume":"33","author":"Baser","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.vhri.2018.05.002_bib0037","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12891-016-1038-3","article-title":"The challenging interplay between rheumatoid arthritis, ageing and comorbidities","volume":"17","author":"Van Onna M","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.vhri.2018.05.002_bib0038","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","article-title":"Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients","volume":"48","author":"K\u00f6ller","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.vhri.2018.05.002_bib0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.vhri.2014.07.004","article-title":"Medical and productivity costs of rheumatoid arthritis in the Czech Republic: cost-of-illness study based on disease severity","volume":"4","author":"Klime\u0161","year":"2014","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2018.05.002_bib0041","first-page":"21","article-title":"Copayments: Too much, yet not enough?","volume":"3","author":"Silverman","year":"2006","journal-title":"Biotechnol Healthc"},{"key":"10.1016\/j.vhri.2018.05.002_bib0043","first-page":"15","article-title":"Medicine pricing interventions\u2014the South African experience","volume":"2","author":"Gray","year":"2009","journal-title":"South Med Rev"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109918301055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109918301055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T23:25:27Z","timestamp":1567293927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109918301055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":36,"alternative-id":["S2212109918301055"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2018.05.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2018.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}